Skip to main content
. Author manuscript; available in PMC: 2016 Oct 1.
Published in final edited form as: Cancer. 2015 Jun 19;121(19):3455–3464. doi: 10.1002/cncr.29538

Figure 2.

Figure 2

Progression-free survival for A) all patients segregated by tumor HPV status and smoking history (P for trend = 0.062), B) all patients segregated by pretreatment serum HPV DNA status and smoking history (P for trend = 0.275), and C) only patients with HPV-positive tumors segregated by pretreatment serum HPV DNA status (P=0.627). Patients with HPV-positive tumors and ≤10 pack-years of smoking had better progression-free survival than did patients with HPV-negative tumors (P=0.020), and there was a borderline significant trend across the 3 groups (P=0.062).